Adalimumab - Safe and Effective Therapy for an Adolescent Patient with Severe Psoriasis and Immune Thrombocytopenia

Acta Dermatovenerol Croat. 2019 Jun;27(2):121-123.

Abstract

Psoriasis has been linked to several comorbidities, including metabolic syndrome, atopy, and celiac disease. However, the association between immune thrombocytopenia and psoriasis has rarely been described. We report the case of an adolescent with severe psoriasis and concomitant immune thrombocytopenia who obtained remission during treatment with adalimumab. Increased concentration of tumor necrosis factor-α seems to be a pathogenic linkage and therapeutic target for both diseases.

Publication types

  • Case Reports

MeSH terms

  • Adalimumab / therapeutic use*
  • Adolescent
  • Female
  • Humans
  • Psoriasis / drug therapy*
  • Purpura, Thrombocytopenic, Idiopathic / drug therapy*
  • Quality of Life
  • Remission Induction

Substances

  • Adalimumab